Storage Conditions Affect Urinary Albumin and Creatinine
By LabMedica International staff writers Posted on 09 Apr 2019 |
Image: The DS2 ELISA Automation System (Photo courtesy of Dynex Technologies).
Moderately increased urinary albumin excretion, formerly known as microalbuminuria, has been established as a risk factor for diabetic kidney disease. Increasing albumin to creatinine ratio (ACR) within the normal range is a risk factor for cardiovascular disease in the general population.
Clinical and epidemiological studies investigating the continuous relationship between albumin excretion and the risk of cardiovascular disease (CVD) often stores urine samples for long durations before measuring the ACR. It is therefore important to understand the stability of ACR during prolonged frozen storage in samples with low levels of albumin, to ensure the reported ACR is valid.
Health experts working with the University of Exeter (Exeter, UK) collect 30 urine samples: 20 from random spot collections and 10 from overnight collections from 17 participants, all without any known disease. The team determined the stability of urinary albumin and creatinine over 12 months in samples stored at -20 ⁰C and -80 ⁰C using an assay which enables assessment of previously undetectable levels of albumin and to investigate if additives can be used to prevent urinary albumin degradation. ACR was measured in 30 urine samples from healthy subjects on the day of collection. Each sample was divided into five portions, each receiving a different treatment; alkalization, protease inhibiter, boric acid, low protein binding tubes and no treatment (control).
Urinary albumin was measured using an enzyme linked immunosorbent assay (ELISA) on a DS2 automated platform. The Orgentec ELISA has a limit of quantification of 0.74mg/L, the limit of detection was 0.24mg/L and within batch coefficient of variation (CV) is <12%. Urinary creatinine was measured by the Jaffe method on the P8000 COBAS analyzer, which demonstrated a within batch CV <4.2%.
The scientists reported that the mean (95% CI) percent change in ACR was -34.3% (-47.2 to -21.4) and -1.8% (-9.4 to 5.8) in samples stored at -20 oC and -80 oC respectively. Treating samples did not prevent the reduction in albumin at -20 oC. Urinary creatinine concentration was reduced (compared to not frozen samples) in untreated samples stored for 12 months at -20 oC and -80 oC. Observed decreases in ACR reflect the change in albumin concentration, however the increase in ACR observed in alkalized samples stored at -20 oC reflects decreased creatinine concentration.
The authors concluded when investigating the relationship between increasing ACR in the normal range and risk of CVD in the general population should store samples at -80 oC if ACR measurement is not carried out on the day of collection. Collecting urine samples in boric acid, storing in low protein binding tubes, pre-treating by alkalization or by adding pepstatin, does not prevent the decline in urinary albumin concentration over 12 months storage at -20 oC. The study was published on March 22, 2019, in the journal Practical Laboratory Medicine.
Related Links:
University of Exeter
Clinical and epidemiological studies investigating the continuous relationship between albumin excretion and the risk of cardiovascular disease (CVD) often stores urine samples for long durations before measuring the ACR. It is therefore important to understand the stability of ACR during prolonged frozen storage in samples with low levels of albumin, to ensure the reported ACR is valid.
Health experts working with the University of Exeter (Exeter, UK) collect 30 urine samples: 20 from random spot collections and 10 from overnight collections from 17 participants, all without any known disease. The team determined the stability of urinary albumin and creatinine over 12 months in samples stored at -20 ⁰C and -80 ⁰C using an assay which enables assessment of previously undetectable levels of albumin and to investigate if additives can be used to prevent urinary albumin degradation. ACR was measured in 30 urine samples from healthy subjects on the day of collection. Each sample was divided into five portions, each receiving a different treatment; alkalization, protease inhibiter, boric acid, low protein binding tubes and no treatment (control).
Urinary albumin was measured using an enzyme linked immunosorbent assay (ELISA) on a DS2 automated platform. The Orgentec ELISA has a limit of quantification of 0.74mg/L, the limit of detection was 0.24mg/L and within batch coefficient of variation (CV) is <12%. Urinary creatinine was measured by the Jaffe method on the P8000 COBAS analyzer, which demonstrated a within batch CV <4.2%.
The scientists reported that the mean (95% CI) percent change in ACR was -34.3% (-47.2 to -21.4) and -1.8% (-9.4 to 5.8) in samples stored at -20 oC and -80 oC respectively. Treating samples did not prevent the reduction in albumin at -20 oC. Urinary creatinine concentration was reduced (compared to not frozen samples) in untreated samples stored for 12 months at -20 oC and -80 oC. Observed decreases in ACR reflect the change in albumin concentration, however the increase in ACR observed in alkalized samples stored at -20 oC reflects decreased creatinine concentration.
The authors concluded when investigating the relationship between increasing ACR in the normal range and risk of CVD in the general population should store samples at -80 oC if ACR measurement is not carried out on the day of collection. Collecting urine samples in boric acid, storing in low protein binding tubes, pre-treating by alkalization or by adding pepstatin, does not prevent the decline in urinary albumin concentration over 12 months storage at -20 oC. The study was published on March 22, 2019, in the journal Practical Laboratory Medicine.
Related Links:
University of Exeter
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms